fulranumab
mAbexperimental
Fulranumab is a monoclonal antibody against nerve growth factor. It was designed for the treatment of pain. — Wikipedia
Clinical trial activity
13 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
11
Phase 3
4
Phase 4
0
Earliest trial started Jan 1, 2005 (NCT02348879)
Timeline
Indications
Studied for
- Arthralgia · Phase 2
- Chronic Pain · Phase 1
- Cystitis · Phase 2
- Cystitis, Interstitial · Phase 2
- Diabetic Neuropathies · Phase 2
- Low Back Pain · Phase 2
- Mononeuropathies · Phase 2
- Neuralgia · Phase 2
- Neuralgia, Postherpetic · Phase 2
- Osteoarthritis · Phase 3
- Osteoarthritis, Hip · Phase 2
- Osteoarthritis, Knee · Phase 2
- Pain · Phase 3
- Urinary Bladder Diseases · Phase 2
- Urologic Diseases · Phase 2
Mechanism of action
- Beta-nerve growth factorINHIBITOR
NGF inhibitor
Potent anti-IL-1ß neutralizing antibody, binds to a unique IL-1ß epitope that is proximal to, but does not overlap with the receptor/ligand interface.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFulranumab ↗
- ChEMBLCHEMBL1743023 ↗
Also known as
- amg 403
- amg-403
- fulranumab
- fulranumab
- fulranumab
- jnj-42160443
- jnj-42160443
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02289716 | Phase 3 | Jul 1, 2015 | Johnson and Johnson |
| NCT02336698 | Phase 3 | Jul 1, 2015 | Johnson and Johnson |
| NCT02336685 | Phase 3 | Jul 1, 2015 | Johnson and Johnson |
| NCT02301234 | Phase 3 | Mar 1, 2015 | Johnson and Johnson |
| NCT01060254 | Phase 2 | Apr 1, 2010 | Johnson and Johnson |
| NCT01094262 | Phase 2 | Apr 1, 2010 | Johnson and Johnson |
| NCT00993018 | Phase 2 | Nov 1, 2009 | Johnson and Johnson |
| NCT00929188 | Phase 2 | Oct 1, 2009 | Johnson and Johnson |
| NCT00973141 | Phase 2 | Sep 1, 2009 | Johnson and Johnson |
| NCT00973024 | Phase 2 | Sep 1, 2009 | Johnson and Johnson |
| NCT00964990 | Phase 2 | Sep 1, 2009 | Johnson and Johnson |
| NCT02318407 | Phase 1 | Dec 1, 2006 | Amgen |
| NCT02348879 | Phase 1 | Jan 1, 2005 | Amgen |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 11 | 11 | 2 | 2009 |
| Amgen | For profit | 2 | 2 | 1 | 2005 |
2 organizations
Page 1 / 1